In this newly funded project, the team will test the safety and efficacy of novel therapeutics that selectively target mitochondrial free radicals. They will gather vital preclinical data in different animal models of neurodegenerative disease that will inform further medicinal chemistry and therapeutic development. Specifically, the project aims to determine whether selective inhibition of mitochondrial reactive oxygen species (ROS) production can reduce neuroinflammation and neurotoxicity associated with Alzheimer’s disease, frontotemporal dementia, and other aging-related disorders.